



Date: 13/02/2020

To,
The Manager,
Listing Compliance Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 13th February, 2020 & Submission of financial results. (Script Id "BAJAJHCARE", Script Code "539872")

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of our Company at their Meeting held today i.e. 13th February 2020, has inter alia, considered and approved the following:

- i. Unaudited Standalone Financial results for the Quarter/Nine months ended on 31st December, 2019 along Limited Review Report thereon.


We wish to inform you that the Board Meeting commenced today at 3.00 p.m. and concluded at 4.35 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**


Mr. Sajankumar Bajaj
Chairman & Managing Director
DIN: 00225950

Encl: Unaudited Financial Results for the Quarter/Nine months ended 31st December, 2019 and Limited Review Report thereon

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagie Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

**PARESH
RAKESH**

ASSOCIATES
Chartered Accountants


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended September 30, 2019 and year to date from April 1, 2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standards "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


**For Paresh Rakesh & Associates
Chartered Accountants**

FRN: 119728W


Rakesh Chaturvedi

M. no: 102075

UDIN: 20102075AAAABA7595



Date: 13th February 2020

Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & PERIOD ENDED ON 31ST DECEMBER, 2019

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended		Nine Months Ended	Year Ended
	31.12.2019	30.09.2019	31.12.2019	31.03.2019
	(UnAudited)	(UnAudited)	(UnAudited)	(Audited)
I. Revenue from operations	9,927.23	10,054.58	29,151.18	37,017.37
II. Other Income	12.30	11.68	31.82	97.17
III. Total Revenue (I+II)	9,939.53	10,066.26	29,183.00	37,114.55
IV. Expenses				
(a) Cost of materials consumed (Including Other Direct Expenses)	7,671.45	8,382.96	23,062.12	29,133.30
(b) Changes in Inventories of Finished Good	-114.43	-311.49	-141.03	-330.20
(c) Employee benefits expense	674.44	773.57	2,083.01	2,461.90
(d) Finance Costs	165.49	157.43	505.59	801.78
(d) Depreciation and amortisation expense	285.17	295.23	874.54	1,141.00
(e) Other expenses	334.03	309.54	954.49	1,489.79
Total Expenses	9,016.14	9,607.24	27,338.72	34,697.57
V. Profit before Exceptional and Extra Ordinary Items	923.39	459.01	1,844.28	2,416.98
VI. Exceptional items	-	-	-	-
VII. Profit before Extra Ordinary Items	923.39	459.01	1,844.28	2,416.98
VIII. Extra Ordinary items	-	-	-	-
IX. Profit Before Tax	923.39	459.01	1,844.28	2,416.98
X. Tax Expense				
(a) Current tax	290.00	110.00	540.00	675.00
(b) Deffered Tax	-4.93	0.76	-6.47	38.92
(c) Earlier Years	0.31	20.52	20.82	72.02
Total Tax Expenses	285.38	131.27	554.35	785.95
XI. Profit (Loss) from Continuing Operations	638.01	327.74	1,289.93	1,631.03
XII. Profit (Loss) from Discontinuing Operations	-	-	-	-
XIII. Profit (Loss) for the period (XI + XII)	638.01	327.74	1,289.93	1,631.03
XIV. Paid-up Equity Share Capital (Face Value Rs. 10/-)	1,379.92	1,379.92	1,379.92	689.96
XV. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year	-	-	-	8198.25
XVI. EPS (Not Annualised) (Refer Note No. 6)				
(a) Basic	4.62	2.38	9.35	11.82
(b) Diluted	4.62	2.38	9.35	11.82

Note :


- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 13th February 2020.
- The Financial Account of the Company are prepared under Indian GAAP as the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019. Ind-AS will be applicable from 1st April 2020.
- Comparative Figures for Quarter and Nine Months ended 31st December 2018 is not provided, since the company was listed in SME segment until 31st March 2019 and was required to prepare & publish half yearly results instead of quaterly results upto 31st March 2019.
- The figures for the previous period have been regrouped whenever necessary.
- The Statement as per Accounting Standard AS - 17 on segment reporting is given as Anneuxre A.
- EPS has been calculated on 13799200 Equity Shares of Rs.10 each including Bonus Issue of 6899600 Fully paid up Equity Shares of Rs.10 each on April 11, 2019, consequently the EPS for previous reporting periods are adjusted accordingly.

Date: 13th February 2020
Place: Thane



By Order of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director



BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER & PERIOD ENDED ON 31ST DECEMBER, 2019

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended		Nine Months Ended	Year Ended
		31.12.2019 (UnAudited)	30.09.2019 (UnAudited)	31/12/2019 (UnAudited)	31.03.2019 (Audited)
A	Segment Revenue (Excluding Intersegment Revenue)				
	Bulk Drugs	9326.81	9280.35	27282.03	36155.31
	Formulations	600.42	774.22	1869.15	862.06
	Total	9,927.23	10,054.57	29,151.18	37,017.37
	Segment Revenue (Intersegment Revenue)				
	Bulk Drugs	503.27	424.70	1,491.31	676.41
	Formulations	20.54	10.80	62.40	85.10
	Total	523.81	435.50	1,553.71	761.51
	Gross Segment Revenue (Including Intersegment Revenue)				
	Bulk Drugs	9830.08	9705.05	28773.34	36831.72
Formulations	620.96	785.01	1931.55	947.17	
Total	10,451.04	10,490.06	30,704.89	37,778.88	
B	II. Segment Results				
	Profit / (Loss) Before Tax & Finance Cost				
	Bulk Drugs	1402.86	910.63	3,401.59	4,956.61
	Formulations	7.65	-5.59	-97.23	-248.06
	Total	1,410.51	905.05	3,304.36	4,708.55
	Less : Interest	165.49	157.43	505.59	801.78
	Other Unallocable Expenditure (Net)	321.63	288.61	954.49	1,489.79
Total Profit Before Tax	923.39	459.01	1,844.28	2,416.98	
C	I. Segment Assets				
	Bulk Drugs	26738.22	25506.47	26,738.22	25,099.65
	Formulations	2322.07	2031.19	2,322.07	1,584.80
	Others	500.31	500.31	500.31	0.31
	Total	29,560.59	28,037.97	29,560.59	26,684.76
	II. Segment Liabilities				
	Bulk Drugs	13988.31	13467.62	13,988.31	12,466.14
	Formulations	532.96	453.74	532.96	331.64
	Others	838.75	554.04	838.75	976.33
	Total	15,360.02	14,475.40	15,360.02	13,774.11
Total Capital Employed	14,200.57	13,562.57	14,200.57	12,910.64	
Total (II+III)	29,560.59	28,037.97	29,560.59	26,684.76	

By Order of the Board
For Bajaj Healthcare Limited

Place : Thane
Date: 13th February 2020



Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director

